TAP Submits I.V. Prevacid NDA; AstraZeneca Plans Q2 Nexium I.V. NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TAP’s requested indication for I.V. Prevacid would give the proton pump inhibitor a similar indication to Wyeth’s Protonix I.V., the only proton pump inhibitor currently available in intravenous form.